Summary To evaluate the use of pretargeted immunoscintigraphy (ISG) in the diagnosis and follow-up of patients with medullary thyroid carcinoma (MTC), we studied 25 patients with histologically proven disease; ISG was repeated after surgery in two patients. The antibody, either an anticarcinoembryonic antigen (CEA) or an antichromogranin A (CgA) biotinylated monoclonal antibody (MAb) or a cocktail of the two biotinylated MAbs was first injected. After 24 h, avidin was administrated i.v., followed by "'In-labelled biotin 24 h later. Fifty-two lesions were visualised. Six primary tumours, diagnosed by increased calcitonin levels, were all correctly diagnosed; 47 recurrences, also suspected by blood tumour markers, were detected and confirmed by cytology or histology. In one case, single photon emission tomography allowed the detection of small lymph nodes with a diameter of 4 -7 mm. These lesions, not judged neoplastic by ultrasound, were confirmed to be neoplastic by fine needle aspiration. Pretargeted ISG correctly localises primary tumours and recurrences in MTC patients, when the only marker of relapse is serum elevation of calcitonin. With this three-step pretargeting method, cocktails of potentially useful MAbs can be used, avoiding false-negative studies that may occur when CEA or CgA are not expressed.
Medullary thyroid carcinoma (MTC) arises from calcitoninsecreting parafollicular cells in the thyroid. Both the sporadic and the familial form are treated by surgery (Chong et al., 1975; Rossi et al., 1980) , as the efficacy of radiotherapy is limited (Samaan et al., 1988) and chemotherapy is ineffective (Rougier et al., 1983; Brunt and Wells, 1987) . Early diagnosis of recurrence or metastasis and accurate localisation of recurrent disease are very important prerequisites for successful surgical excision.
Elevated serum calcitonin (Ct) is considered to be a marker for MTC. High serum levels of Ct and carcinoembryonic antigen (CEA) can often be found in patients with recurrent disease several years before it becomes clinically apparent, but, at present, no efficient and specific method is available for the localisation of recurrences.
Morphological imaging techniques (ultrasonography, US; computerised tomography, CT; magnetic resonance imaging, MRI) are routinely used to confirm and localise a biologically detected recurrence but are not always adequate because of topographic polymorphism and the small size of tumour recurrences at an early stage of development (Schwerk et al., 1985; Frank et al., 1987; Crow et al., 1989) .
Several methods based on tumour avidity of non-specific radiopharmaceuticals such as [99"Tc](V)DMSA, '3I11231-MIBG and 20'T1 have also been designed for this purpose, with variable results (Arnstein et al., 1986; Hilditch et al., 1986; Baulieu et al., 1987; Clarke et al., 1987; Hilditch, 1987; Clarke et al., 1988; Hoefnagel et al., 1988; Guerra et al., 1989; Adams et al., 1990; Charkes et al., 1990; Udelsman et al., 1993) .
In the attempt to specifically localise tumour in vivo, MAbs directed to tumour-associated antigens and labelled with gamma-emitting isotopes can be used (Goldenberg et al., 1980; Larson, 1985) . The sensitivity of this technique can be enhanced by lowering the background with tumour pretargeting strategies (Hnatowich et al., 1987; Goodwin et al., 1988;  Correspondence: F Fazio, Department Rowlinson et al., 1988; Domogatsky, 1989; Le Doussal et al., 1989; Kalofonos et al., 1990; Peltier et al., 1993) . When tumour targeting is separated from injection of the radiolabel, injection of the radiotracer can be delayed to a time when circulating MAbs are removed from the blood and consequently background activity is low. Some of these strategies have the potential additional advantage of being able to target the tumour with different antibodies at the same time. One of these strategies, based on the avidin-biotin system, involves the injection of biotinylated MAbs (first step), followed by avidin administration (second step) to precipitate circulating biotinylated MAbs and, at the same time, to target the tumour cells for adequate homing in of the subsequently radiolabelled biotin (third step) (Paganelli et al., 1991) . In this case a cocktail of MAbs could be injected i.v. as first step. Positive immunohistochemical stains for Ct and CEA are characteristic of MTC (De Lellis et al., 1978; Talerman et al., 1979; Pacini et al., 1991) . Recent immunohistochemical studies have established that MTC also stains positively for chromogranin A (CgA) (Schmid et al., 1987) , a glycoprotein stored and released by exocytosis together with the resident hormones of electron-dense core secretory granules in apudomas.
This paper reports the evaluation of pretargeted immunoscintigraphy (ISG) in the diagnosis of primary/metastatic and recurrent MTC. As antibodies, anti-CEA and anti-CgA (separately and as a cocktail) biotinylated MAbs were used in a three-step procedure. MAbs were biotinylated by Societ'a Prodotti Antibiotici (S.P.A., Milano, Italy) as previously described (Paganelli et al., 1991) . The degree of biotinylation was 5 + 1 biotin per antibody determined spectrophotometrically, after protein digestion, as described (Hnatowich et al., 1987) . At this grade of biotinylation the retained immunoreactivity of the antibodies was more than 90%, as tested in a standard ELISA system (Paganelli et al., 1991 Toxicity and immunogenicity All patients were closely observed for 2 h following administration of avidin. Blood samples (10 ml) were obtained in appropriate tubes just before the administration of avidin, then 10-15 days following the injection. All samples were sent out both for routine blood tests as well as to assess the human anti-mouse immunoglobulin (HAMA) and anti-avidin response (HAAR).
Materials and methods

Patients
The induction of human anti-mouse immunoglobulin antibodies was investigated using an ELISA system (Seccamani et al., 1989) in only 11 patients. In fact, our patients being a continuous sequence of patients attending endocrine and oncological clinics of various cities in Italy, they were not always willing to come back for blood tests. In these patients, avidin immunogenicity was studied on microwell plates coated with avidin or streptavidin separately. The plates were saturated for 1 h with PBS/3% bovine serum albumin (BSA). Human sera dilutions were added and incubated for 1 h at 37°C. After five washes, the binding of human anti-avidin antibodies was revealed with horseradish peroxidase-conjugated rabbit anti-human Ig antibodies (Dako) diluted 1:1000, for 45 min at 37°C. After six washes, the enzymatic reaction was developed with a chromogenic substrate (o-phenylendiamine; Sorin Biomedica, Saluggia, Italy) for 10 min and blocked by addition of 1 M sulphuric acid. The optical density reading was 492 nm.
ISG study
The three-step protocol used has been described previously (Paganelli et al., 1991 analysis was carried out on the scores of tracer uptake from the three sections considered. A kappa test (Fleiss, 1980) was used to test inter-observer agreement.
Results
No toxicity was observed. Out of the 11 patients tested, one developed a weak antibody response against mouse immunoglobulins whereas six patients demonstrated antiavidin antibodies 10 -15 days after injection.
The kappa test demonstrated a strong agreement between the two observers (K > 0.75) both for planar and for tomographic images.
ISG results were classified as true positive (TP), true negative (TN), false positive (FP) and false negative (FN) according to histological diagnosis.
ISG results, final diagnoses and classifications are reported in Table II . Figure 1 reports the overall distribution of activity in a typical patient. Activity biodistribution in the three-step pretargeting method using anti-CEA MAbs was compared with that obtained in the conventional ISG using the same antibody as Paganelli et al. (1991) . No liver uptake and a negligible bone marrow uptake were demonstrated.
Fifty-two lesions were visualised by SPET and all verified by histology or cytology. Only three of these 52 lesions were visualised on planar spot views (patients 2, 16 and 23).
Fifty lesions were TP and two FP. In these two cases (patients 20, 21), metastatic lymph nodes visualised by ISG were not found at surgery. The smallest lesion detected by SPET was a right laterocervical lymph node of 4 mm in diameter. Two lymph nodes (patients 6, 21) identified as MTC metastases at histology were not visualised by ISG (two FN).
As regards patient 9 (TN, Table II), he had an abnormal Ct response to pentagastrin stimulation; ISG study did not show abnormal thyroid uptake of the tracer. The patient underwent surgery, and histology revealed a nodular hyperplasia as a colloid goiter. Medullary thyroid carcinoma is an uncommon tumour that frequently metastasises to cervical and mediastinal lymph nodes, bone and lung (Brunt and Wells, 1987) . Ct and CEA are very sensitive indicators of MTC and are currently used as serum markers for relapse or distant metastases after thyroidectomy. Localisation of the tumour may be a more Figure 1 Whole-body biodistribution obtained 2 h after the injection of radioactivity. Most of the activity is already excreted by the kidneys (k) with high levels in the bladder (B). Please note the absence of activity in the liver and skeleton. Some biotin is also excreted in the mammary glands (arrow). R, right. complicated problem. US is useful in the post-surgical followup of MTC patients in order to evaluate cervical lymph nodes and relapse, but it is not specific (Schwerk et al., 1985) . MRI has similar indications and it can also be used in the evaluation of the mediastinum (Crow et al., 1989) . Various [99mTc](V)DMSA, 1111231_MIBG and 201T1 show different sensitivities of lesion detection in different reports (Arnstein et al., 1986; Hilditch et al., 1986 Hilditch et al., , 1987 Baulieu et al., 1987; Clarke et al., 1987 Clarke et al., , 1988 Hoefnagel et al., 1988; Adams et al., 1990; Guerra et al., 1989; Charkes et al., 1990; Udelsman et al., 1993) . These different sensitivities can be related to patient selection, limited number of patients studied, Ct blood levels, dimension of lesions studied or to methodological problems. For example, Clarke et al. (1987 Clarke et al. ( , 1988 reported a sensitivity of 74% in 19 patients using
[99mTc](V)DMSA, Mojiminiyi et al. (1989) correctly diagnosed seven out of eight patients, Hilditch et al. could not reveal abnormal foci of tracer uptake in any of five MTC patients in a first work (Hilditch et al., 1987) , whereas in a subsequent work (Hilditch et al., 1988) they correctly diagnosed three out of four MTC patients. These are certainly good results; however, they were obtained in too few patients.
In vivo tumour localisation can be obtained using radiolabelled monoclonal antibodies directed against tumour-associated antigens. Thus ISG is very specific, but a relatively low tumour to background ratio and a high background activity can affect its sensitivity. Theoretically ISG can target different MTC-associated antigens, such as Ct, CEA and CgA (De Lellis et al., 1978; Talerman et al., 1979; Schmid-et al., 1987; Pacini et al., 1991) . MTC often produces CEA, which is expressed both in the cytoplasm and on the cell membrane. On the contrary, Ct is expressed within the cytoplasm. In our pretargeting protocol, the most appropriate target antigen must be available on the cell surface. This happens because biotinylated MAb binds to the antigen and becomes, in its turn, the 'antigen' for the cold avidin and the radiotracer. Recently, a positive immunostaining for CgA in MTC has also been described: the staining for CgA correlates with the areas staining positively for calcitonin (Schmid et al., 1987) . CgA is released by neuroendocrine tumours without physiological neuroendocrine stimuli and is present in a significant amount in the intracellular matrix of such tumours.
Several studies have shown the capability of ISG performed with '"'I or "'In-labelled anti-CEA MAb to visualise MTC recurrences (Berche et al., 1982; Reiners et al., 1986; Edington et al., 1988; Manil et al., 1989; Zanin et al., 1990; O'Byrne et al., 1992; Vuillez et al., 1992) . However, after injection of directly labelled MAb, image interpretation is sometimes difficult because of non-specific bone marrow, vascular and liver activity (Peltier et al., 1993) . In CEApositive tumours, gliomas and lung cancers (Paganelli et al., 1994a; Dosio et al., 1994) , and more recently in neuroendocrine tumours using an anti-CgA MAb (Colombo et al., 1993) , the avidin-biotin pretargeting method provides good results and offers several advantages over the administration of directly labelled MAbs. A fast label clearance and removal of circulating antibodies, with low background radioactivity levels, and the preservation of MAb immunoreactivity (Paganelli et al., 1991) were demonstrated. In addition the second and third step of this three-step protocol can be common to all studies, irrespective of the specificity of the anti-tumour MAb, and potentially useful MAbs can be injected in sequence or even in combination, as we did, as the first step. In this way, radiolabelled biotin can serve as a single carrier of diagnostic or therapeutic radionuclides in patients receiving cocktails of antibodies.
In the present study, four patients underwent ISG using, for the first step, a cocktail of MAbs that recognises different tumour-associated antigens (CEA and CgA) Matzku et al., 1989) . As No relationship between CEA serum levels and ISG sensitivity was found. Four patients who underwent anti-CEA ISG studies had normal CEA serum levels and TP scans. Thus. ISG using anti-CEA MAb is effective even when Ct alone is elevated.
All primary tumours were visualised. In addition. a patient with C-cell hyperplasia. considered a preneoplastic condition. was correctly diagnosed. and in a patient with normal Ct serum levels a pathological uptake of the tracer was demonstrated by ISG and subsequently confirmed by histology.
Fifty out of 52 tumour recurrences (96%) were imaged and confirmed by cytology or histology.
Tomographic ISG study was crucial for detecting small lymph nodes. with a diameter of 4-7 mm. that were not recognised as neoplastic by US. Moreover the presence of blood activity. although low with respect to directly labelled MAbs. could make it difficult to distinguish lymph node activity from vascular background (see Figures 4-6) on planar images. whereas using SPET the separation of tumour from background activity is feasible.
A patient whose US and CT scans revealed a liver lesion had a negative ISG liver scan. and histology subsequently revealed the benign nature of the lesion.
One potential disadvantage of this pretargeting protocol is the immunogenicity of avidin. The immunogenicity of biotinylated antibodies and avidin was tested in only 11 patients. However, data available from 60 other patients receiving, in similar protocols. biotinylated antibodies (i.e. anti-tenascin. anti-CEA and anti-CgA) and avidin. comply with the results of this study. In particular, none of the patients studied developed an important response to mouse immunoglobulin after the injection of 1 mg of biotinylated IgG and 22% developed HAAR after the injection of 5-6 mg of avidin (unpublished data).
In conclusion, pretargeted ISG with CEA and or CgA MAb may be useful in MTC follow-up, when the only marker of relapse is serum elevation of Ct. in order to localise tumour recurrences. and in the early detection of preneoplastic conditions. such as C-cell hyperplasia.
With this method, radiolabelled biotin can serve as a carrier not only for diagnostic but also for therapeutic purposes. However, radioactivity delivered per gram of tumour is still below the optimal dose for radioimmunotherapy (Paganelli et al., 1994b) . A higher tumour radioactivity could be obtained by using more biotinylated MAbs in the first step and streptavidin in the second step, as this results in a better avidination of the tumour. As avidin blood clearance is very fast, the longer plasma t, . of streptavidin can convey more streptavidin and so more radiolabelled biotin to the tumour. However, streptavidin may be more immunogenic than avidin when injected in humans (unpublished data). Methods to block this response are currently under evaluation and it is anticipated that advances in molecular biology and recombinant DNA technology will contribute significantly to circumventing this problem. By optimising the radioactivity channelled onto the tumour and by labelling biotin with f-emitting isotopes. such as 9Y and '88Re, antibody-guided therapy of small MTC recurrences may be feasible.
